Abstracts

REPROGRAMMING CMV-SPECIFIC CD8+ T CELLS TO TARGET HIV USING TCR GENE TRANSFER

Background: Due to the chronic nature of HIV infection, cytotoxic CD8 T lymphocytes (CTL) are limited in their capacity to provide sustained control of HIV infection in part due to exhaustion. In contrast, chronic cytomegalovirus (CMV) infection induces a unique CTL response termed memory inflation characterized by continued expansion following priming, maintained “effector‐memory” phenotype, and…

CLINICAL OUTCOMES AMONG IN- AND OUTPATIENTS WITH MPOX IN AN URBAN HEALTH SYSTEM

Background: During the 2022 mpox outbreak, most patients were managed as outpatients, however many required hospitalization. We describe demographics, indications for hospitalization, therapeutic interventions and risk factors associated with hospitalization among patients with mpox in an urban health system. Methods: Patients in the Johns Hopkins Health System (JHHS) with an mpox diagnosis from July 1…

MPOX VIRAL LOAD BY SPECIMEN TYPE AND DIAGNOSTIC TESTING IN A CLINICAL LABORATORY

Background: Unprecedented person-to-person transmission of MPOX (monkeypox virus) occurred in multiple countries in 2022, raising demand for diagnostic testing and generating uncertainty regarding optimal specimen types. A qualitative real-time PCR assay for the detection of MPOX DNA was validated and implemented in our clinical virology laboratory in August 2022, serving a high-risk population in both…

DEVELOPMENT AND PILOT OF AN MPOX SEVERITY SCORING SYSTEM (MPOX-SSS)

Background: Clinical severity scores facilitate standardized quantitative comparison of disease severity between groups of patients to understand risk factors for severe illness and evaluate treatment efficacy. Relevant severity scoring tools provide reliable discrimination across the spectrum of illness severity and are parsimonious, easy to use, and universally applicable. Prior mpox severity scores, based on numbers…

MOSAIC CLADE 2B MPOX COHORT STUDY: CLINICAL CHARACTERISATION AND OUTCOMES

Background: Over 80,000 cases of clade 2b Mpox were reported in 2022 outside traditionally endemic African countries. The transmission and features of clade 2b Mpox differ from clade 1, requiring systematic clinical characterisation. Methods: MOSAIC is a cohort study of clinical and virological outcomes of patients with laboratory-confirmed Mpox in 10 European countries started in…

A PLACEBO-CONTROLLED RANDOMIZED TRIAL OF THE HTI IMMUNOGEN VACCINE AND VESATOLIMOD

Background: In early-treated people with HIV (PWH), the HIV-specific T cell response induced by a combination of DNA.HTI (D), MVA.HTI (M) and ChAdOx1.HTI (C) vaccines was associated with longer time off antiretroviral therapy (ART) during analytical treatment interruption (ATI) (AELIX-002; Bailón L et al. Nat Med 2022). AELIX-003 (NCT04364035) was a double-blind, randomized (2:1), multi-center…